GRI Bio, Inc. (GRI)
NASDAQ: GRI · Real-Time Price · USD
1.820
-0.140 (-7.14%)
At close: Jun 26, 2026, 4:00 PM EDT
1.880
+0.060 (3.30%)
After-hours: Jun 26, 2026, 7:51 PM EDT
GRI Bio Employees
GRI Bio had 4 employees as of December 31, 2025. The number of employees did not change compared to the previous year.
Employees
4
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$2,727,000
Market Cap
3.22M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 4 | 0 | - |
| Dec 31, 2024 | 4 | 0 | - |
| Dec 31, 2023 | 4 | 3 | 300.00% |
| Dec 31, 2022 | 1 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Calidi Biotherapeutics | 29 |
| VivoSim Labs | 14 |
| Azitra | 13 |
| Decoy Therapeutics | 11 |
| Revelation Biosciences | 9 |
| Galmed Pharmaceuticals | 6 |
| CDT Equity | 4 |
| SciSparc | 3 |
GRI News
- 10 days ago - GRI Bio announces U.S. FDA granted ODD to GRI-0621 - TheFly
- 10 days ago - GRI Bio Secures FDA Orphan Drug Designation for GRI-0621 (Tazarotene) in Idiopathic Pulmonary Fibrosis - GlobeNewsWire
- 11 days ago - GRI Bio granted FDA orphan designation for tazarotene - TheFly
- 5 weeks ago - GRI Bio to Present at A.G.P.'s Annual Healthcare Company Showcase - GlobeNewsWire
- 6 weeks ago - GRI Bio Reports First Quarter 2026 Financial Results, New Data Reinforcing Differentiated Profile of GRI-0621 in Idiopathic Pulmonary Fibrosis and Highlights Continued Advancement of Differentiated Immune-Modulating Pipeline - GlobeNewsWire
- 6 weeks ago - GRI Bio Quarterly report: Q1 2026 - Filings
- 6 weeks ago - GRI Bio Earnings release: Q1 2026 - Filings
- 2 months ago - GRI Bio receives UAE patent allowance for inflammatory disease treatments - TheFly